7,871 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 7,871 shares of the biopharmaceutical company’s stock, valued at approximately $577,000.

A number of other large investors also recently made changes to their positions in the business. DLD Asset Management LP acquired a new position in Halozyme Therapeutics in the second quarter valued at $650,250,000. Arrowstreet Capital Limited Partnership grew its holdings in Halozyme Therapeutics by 127.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after buying an additional 1,425,674 shares during the period. Federated Hermes Inc. increased its stake in shares of Halozyme Therapeutics by 294.1% during the 3rd quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after acquiring an additional 1,082,638 shares during the last quarter. LSV Asset Management lifted its holdings in shares of Halozyme Therapeutics by 0.9% during the 3rd quarter. LSV Asset Management now owns 1,266,027 shares of the biopharmaceutical company’s stock worth $92,850,000 after acquiring an additional 10,787 shares during the period. Finally, Royal London Asset Management Ltd. lifted its holdings in shares of Halozyme Therapeutics by 122.3% during the 2nd quarter. Royal London Asset Management Ltd. now owns 1,101,912 shares of the biopharmaceutical company’s stock worth $57,321,000 after acquiring an additional 606,236 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 0.5%

Shares of NASDAQ HALO opened at $70.64 on Tuesday. The stock has a fifty day moving average price of $72.29 and a 200 day moving average price of $70.54. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22. The company has a market cap of $8.34 billion, a P/E ratio of 28.37, a P/E/G ratio of 0.29 and a beta of 0.97.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million during the quarter, compared to analysts’ expectations of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.Halozyme Therapeutics’s quarterly revenue was up 51.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on HALO shares. Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. The Goldman Sachs Group reiterated a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Finally, TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $78.56.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $78.64, for a total value of $786,400.00. Following the completion of the transaction, the chief executive officer directly owned 708,719 shares in the company, valued at approximately $55,733,662.16. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the sale, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 49,398 shares of company stock valued at $3,650,592 in the last ninety days. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.